COMMUNIQUÉS West-GlobeNewswire
-
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
03/03/2026 -
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
03/03/2026 -
PathAI Receives U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI-Powered Pathology Solution to Transform Dermatopathology Workflow
03/03/2026 -
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
03/03/2026 -
Exagen Inc. to Participate in Upcoming Investor Conferences
03/03/2026 -
LiveWorld Launches Integrated GEO, AIO and SEO Search Optimization for Healthcare and Pharma Brands
03/03/2026 -
Hot Springs Arkansas Neurologist Kara Way Opens New Way Neurology
03/03/2026 -
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
03/03/2026 -
Immix Biopharma to Participate in Upcoming Investor Conferences
03/03/2026 -
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
03/03/2026 -
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
03/03/2026 -
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
03/03/2026 -
rYojbaba Announces $3.2 Million Comprehensive Global Labor Support and Union Infrastructure Development Agreement with International Labor Union
03/03/2026 -
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
03/03/2026 -
Vericel to Present at Multiple Upcoming Investor Conferences
03/03/2026 -
THC Therapeutics, Inc. Announces Filing of 10-K and Provides Corporate Update
03/03/2026 -
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03/03/2026 -
TOMI Environmental Solutions Appoints Total Clean Air as Preferred European Partner for SteraMist iHP Decontamination Technology
03/03/2026 -
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
03/03/2026
Pages